RIANA Therapeutics, a startup spun out of the University of Veterinary Medicine Vienna, is developing novel anti-cancer drugs based on scientific findings from Vetmeduni’s Moriggl research group. The company’s proprietary platform technology targets cancer-causing protein-protein interactions, selectively targeting only malignant oncogenes. RIANA’s first molecule with a Dr. Jekyll and Mr. Hyde problem for which oligomerization inhibitors were successfully identified is STAT5B, a molecule that promotes the development of lymphomas, leukaemia and solid tumours. RIANA expects its compounds to have significantly fewer side effects while maintaining good efficacy.